Sentences with phrase «by immune checkpoint»

Detection of immune cell checkpoint and functional markers in the lung TME: The field of cancer immunotherapy continues to expand rapidly over recent years, with promising clinical results by immune checkpoint inhibitors and other therapeutic approaches.

The cancer cells» defense strategy can be overcome by immune checkpoint inhibitor agents, including anti-PD-1 / PD - L1 antibodies, several kinds of which have received fast - track approval from the U.S. Food and Drug Administration (FDA).

Not exact matches

By administering a complementary antibody, they blocked the function of two such immune checkpoints, whereby different types of endogenous T - cells were activated.

The class of medications that he conceived, known as immune checkpoint inhibitors, works counterintuitively: By turning off one of the immune system's built - in safeguards, the inhibitors allow T cells — the system's foot soldiers — to attack tumors more effectively.

However, immune cells may be blocked by inhibitory molecules, which serve as checkpoints to alleviate or «turn off» the immune system response, Gu explained.

Known as a checkpoint inhibitor, tremelimumab is an investigational monoclonal antibody that «cuts the brakes» of the immune system by targeting cytotoxic T - lymphocyte antigen 4 (CTLA - 4), a protein that can switch off a patient's immune response.

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer — a median 17.5 months vs. 12.7 months — if they simultaneously received an immune stimulant, according to a study led by Dana - Farber Cancer Institute scientists.

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

They have identified a «checkpoint» manned by these immune cells that, if barred, can halt the development of the lung inflammation associated with allergies.

Allison pioneered immune checkpoint blockade, an approach that treats the immune system, rather than the tumor directly, by blocking molecules on T cells that shut those attack cells down, protecting tumors from immune response.

«Cancers evade immunotherapy by «discarding the evidence» of tumor - specific mutations: Discovery could explain widespread acquired resistance among patients treated with immune checkpoint blockade drugs.»

Researchers led by Van Allen and Choueiri sought an explanation for why some patients with a form of metastatic kidney cancer called clear cell renal cell cancer (ccRCC) gain clinical benefit — sometimes durable — from treatment with immune checkpoint inhibitors that block the PD - 1 checkpoint, while other patients don't.

Checkpoint blockade therapy works by interfering with cancer's ability to turn off the body's immune reaction.

Microbes that cause diseases like HIV, malaria, and hepatitis C exploit and often activate the same checkpoint pathways — cell surface receptors such as CTLA4 and PD - 1 — to slow immune cells and prevent their elimination by the host.

Checkpoint blockade: Fewer but stronger results Allison pioneered immune checkpoint blockade, an approach that treats the immune system, rather than the tumor directly, by blocking molecules on T cells that shut those attack cells down, protecting tumors from immuneCheckpoint blockade: Fewer but stronger results Allison pioneered immune checkpoint blockade, an approach that treats the immune system, rather than the tumor directly, by blocking molecules on T cells that shut those attack cells down, protecting tumors from immunecheckpoint blockade, an approach that treats the immune system, rather than the tumor directly, by blocking molecules on T cells that shut those attack cells down, protecting tumors from immune response.

The drugs, ipilimumab (Yervoy ®) and nivolumab (Opdivo ®), made by Bristol - Myers Squibb (BMS), are two immune checkpoint inhibitors that «release the brakes» on the immune system, allowing it to mount a stronger and more effective attack against cancer.

The data presented provide new insights on the potential mechanism by which Seres» microbiome therapies could improve the outcomes of cancer patients treated with immune checkpoint inhibitors.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

T - cells (red, yellow, and blue) attack a tumour in a mouse model of breast cancer following treatment with radiation and a PD - L1 immune checkpoint inhibitor, as seen by transparent tumour tomography.

The first generation of immunotherapies, including immune checkpoint inhibitors and cancer vaccines, have been limited by the proportion of patients who benefit, and by the depth and duration of response in those that do.

PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration.

In an effort to further exploit the potential of Pexa - Vec to activate the immune system to fight cancer, as seen in McDonald's preclinical data, SillaJen recently announced a new clinical trial in collaboration with New York - based Regeneron Inc. to test Pexa - Vec and REGN2810, a PD - 1 checkpoint inhibitor, in combination against renal cell carcinoma, and recently signed a sponsored research agreement with UCSF to enable joint support of parallel preclinical experiments by McDonald's team.

The company is trying to combine and commercialize two very hot technologies — adoptive T - cell therapy and silencing of immune checkpoints by RNAi.

Do you think if I tried to explain what immunotherapy is by mentioning signalling pathways, immune checkpoints or cytokines, my message would be effectively transmitted?

Their work encompasses several strategies, including: developing FL - HCC animal models to characterize tumor - immune interactions, exploring if a mutated protein associated with FL - HCC could be targeted by immunotherapy, identifying immune checkpoints that could potentially serve as targets for immunotherapy as well as biomarkers for analyzing patients, and evaluating the effectiveness of immunotherapy strategies against FL - HCC patient samples in the lab.

By blocking these inhibitory molecules or, alternatively, activating stimulatory molecules, checkpoint inhibitors are designed to unleash or enhance pre-existing anti-cancer immune responses.

This position, funded by Cancer Research UK, will explore whether manipulation of a novel antigen presentation checkpoint can enhance the repertoire of tumour antigens presented for immune recognition.

The final aim is improving therapeutic effect and defining rationalized drug combinations with immune checkpoints and proprietary molecules developed by collaborators, including novel immunomodulatory approaches generated at our unit.

Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first - line treatment for advanced, non-squamous NSCLC.

Immunotherapies may also stimulate immune responses controlled by these checkpoints.

His work also suggests that therapies designed to block immune checkpoints, such as anti-PD-1 antibodies, may act in part by shifting this metabolic competition back in favor of immune cells.

In melanoma, an increase in overall mutational and neoantigen load — novel tumor - specific antigens that can be recognized by the immune system — was associated with clinical benefit from checkpoint blockade.

It is also the first in an emerging class of therapies called «checkpoint blockade,» which enhance the immune system's ability to attack cancer by interfering with immunological checkpoints that slow or stop immune cell activation and proliferation in the presence of tumors or chronic viral infection.

The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.

iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting IDO1, A2A, TIGIT immune checkpoint and non-immunogenic («cold») tumours.